Pancreatic mucinous cystadenocarcinoma in a patient harbouring
BRCA1 gene
Case report
Mucinous cystadenocarcinoma
Olaparib
Pancreatic cancer
Journal
World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470
Informations de publication
Date de publication:
15 Dec 2020
15 Dec 2020
Historique:
received:
13
10
2020
revised:
01
11
2020
accepted:
10
11
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
29
12
2020
Statut:
ppublish
Résumé
Pancreatic mucinous cystadenocarcinoma (MCAC) is a rare malignancy with a poor prognosis when it presents metastases at diagnosis. Due to its very low incidence, there are no clear recommendations for the treatment of advanced disease. Olaparib (an oral PARP inhibitor) has been approved for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma harbouring germline A 41-year-old woman, without personal or family history of cancer, was diagnosed with ovarian and peritoneal metastases of MCAC. She underwent 12 cycles of gemcitabine plus oxaliplatin (GEMOX) obtaining a partial response and allowing radical surgery. One year later, local recurrence was documented, and other 12 cycles of GEMOX were administered obtaining a complete response. Seven years later, another local recurrence, not amenable to surgical resection, was diagnosed. She started FOLFIRINOX (oxaliplatin, irinotecan, leucovorin and fluorouracil), obtaining a partial response after 8 cycles. Given the excellent response to platinum-based chemotherapy, The current case suggests the beneficial effect of olaparib in
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic mucinous cystadenocarcinoma (MCAC) is a rare malignancy with a poor prognosis when it presents metastases at diagnosis. Due to its very low incidence, there are no clear recommendations for the treatment of advanced disease. Olaparib (an oral PARP inhibitor) has been approved for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma harbouring germline
CASE SUMMARY
METHODS
A 41-year-old woman, without personal or family history of cancer, was diagnosed with ovarian and peritoneal metastases of MCAC. She underwent 12 cycles of gemcitabine plus oxaliplatin (GEMOX) obtaining a partial response and allowing radical surgery. One year later, local recurrence was documented, and other 12 cycles of GEMOX were administered obtaining a complete response. Seven years later, another local recurrence, not amenable to surgical resection, was diagnosed. She started FOLFIRINOX (oxaliplatin, irinotecan, leucovorin and fluorouracil), obtaining a partial response after 8 cycles. Given the excellent response to platinum-based chemotherapy,
CONCLUSION
CONCLUSIONS
The current case suggests the beneficial effect of olaparib in
Identifiants
pubmed: 33362915
doi: 10.4251/wjgo.v12.i12.1456
pmc: PMC7739147
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1456-1463Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Références
Eur J Surg Oncol. 1996 Jun;22(3):232-6
pubmed: 8654602
N Engl J Med. 2003 Jun 5;348(23):2339-47
pubmed: 12788999
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Clin Gastroenterol Hepatol. 2004 Nov;2(11):1026-31
pubmed: 15551256
Surgery. 2012 Sep;152(3 Suppl 1):S4-12
pubmed: 22770958
Pancreas. 2018 Jul;47(6):759-771
pubmed: 29771769
Hum Pathol. 2014 Nov;45(11):2341-6
pubmed: 25248573
N Engl J Med. 2019 Jul 25;381(4):317-327
pubmed: 31157963
Pancreas. 2019 Jul;48(6):817-822
pubmed: 31210663
J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6
pubmed: 10433620
Br J Cancer. 2014 Sep 9;111(6):1132-8
pubmed: 25072261
J Clin Oncol. 2017 Oct 20;35(30):3382-3390
pubmed: 28767289
Int J Surg. 2016 Nov;35:76-82
pubmed: 27638187
Gynecol Oncol. 2015 May;137(2):343-50
pubmed: 25725131
Ann Surg. 1999 Aug;230(2):152-61
pubmed: 10450728
Br J Cancer. 2020 Feb;122(3):333-339
pubmed: 31787751
J Clin Oncol. 2015 Oct 1;33(28):3124-9
pubmed: 25940717
Asian J Androl. 2012 May;14(3):409-14
pubmed: 22522501
Gan To Kagaku Ryoho. 2009 Jun;36(6):995-8
pubmed: 19542723
Cancer Manag Res. 2020 Apr 23;12:2731-2742
pubmed: 32368150
Pancreatology. 2012 May-Jun;12(3):183-97
pubmed: 22687371
J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65
pubmed: 12237281
JAMA. 2016 May 3;315(17):1882-93
pubmed: 27139061
Pancreatology. 2006;6(1-2):17-32
pubmed: 16327281
Ann Gastroenterol. 2011;24(3):213-217
pubmed: 24713784